B
Birgit Jung
Researcher at Boehringer Ingelheim
Publications - 154
Citations - 2675
Birgit Jung is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Bicyclic molecule & Aryl. The author has an hindex of 29, co-authored 152 publications receiving 2557 citations.
Papers
More filters
Journal ArticleDOI
Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke.
Kiyoshi Takeyama,Birgit Jung,Jae Jeong Shim,Pierre-Régis Burgel,Trang Dao-Pick,Iris F. Ueki,Ursula Protin,Peer Kroschel,Jay A. Nadel +8 more
TL;DR: Activation of epidermal growth factor receptors (EGFR) is responsible for mucin production after inhalation of cigarette smoke in airways in vitro and in vivo, and may provide a novel strategy for therapy in airway hypersecretory diseases.
Journal ArticleDOI
BAL Cell Gene Expression is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis
Antje Prasse,Harald Binder,Jonas C. Schupp,Gian Kayser,Elena Bargagli,Benedikt Jaeger,Moritz Hess,Susanne Rittinghausen,Louis J. Vuga,Heather Lynn,Shelia M. Violette,Birgit Jung,Karsten Quast,Bart M. Vanaudenaerde,Yan Xu,Jens M. Hohlfeld,Norbert Krug,Jose D. Herazo-Maya,Paola Rottoli,Wim A. Wuyts,Naftali Kaminski +20 more
TL;DR: In this article, the authors determine whether BAL cell gene expression is predictive of survival in IPF patients, and they show that it is not predictive of lung cancer survival with variable and unpredictable course.
Patent
Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
TL;DR: In this paper, the use of the inventive bicyclic heterocycles for treating illnesses, especially tumor diseases, diseases of the lung and of the respiratory tract, and relates to the production of inventive compounds.
Patent
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
TL;DR: In this paper, the present invention relates to bicyclic heterocyclic compounds of general formula (I), wherein R a to R d, A to D and X are defined as in claims 1 to 8, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties.
Journal ArticleDOI
Involvement of substance P in scratching behaviour in an atopic dermatitis model.
TL;DR: The results suggest that clinical trials of tachykinin NK1 antagonists for the treatment of itching in atopic dermatitis patients would be warranted.